Abstract 962P
Background
Stereotactic radiotherapy (SBRT) has shown promising for unresectable hepatocellular carcinoma (HCC) due to its ability to modulate the tumor immune microenvironment. Methyl-CpG binding domain protein 3 (MBD3) is highly expressed in HCC and negatively correlated with prognosis. However, the role of MBD3 in the radioimmunology of SBRT in HCC remains unclear.
Methods
The expression and correlation of MBD3 and programmed cell death ligand 1 (PD-L1) were analyzed in HCC tissues before and after SBRT by immunohistochemistry (IHC). The mechanic regulations of MBD3 in the radioimmunology of SBRT in HCC were investigated both in vitro and in vivo studies.
Results
We observed a significant increase of PD-L1 in HCC after SBRT, which was associated with decreased MBD3 expression. As the radiation dose increased, MBD3 gradually degraded, while PD-L1 gradually upregulated in human and murine liver cancer cells. Through RNA sequencing, KEGG enrichment analysis and in vitro experiments, we identified that IL-6 was massively activated and released, leading to the activation of the JAK1/STAT3 signaling pathway, and ultimately resulted in the upregulation of PD-L1, which were induced by MBD3 degradation in liver cancer cells by irradiation. In vivo experiments showed that the combination of SBRT and PD-L1 blockade significantly enhanced the antitumor efficacy in the murine orthotopic model of HCC, partly dependent on the increased infiltration of IFNγ+CD8+T cells in the tumor. We also found that SBRT reactivated proteinase-activated receptor 2 (PAR2) to promote the release of IL-6, activating the JAK1/STAT3 signaling pathway, leading to the upregulation of PD-L1 through relieving the inhibition of F2RL1 (encoding PAR2) mediated by the deacetylation of the MBD3/NuRD complex. Our findings were further confirmed by IHC analysis of the above proteins in HCC tissues before and after SBRT.
Conclusions
Our study suggests that SBRT can reprogram the tumor immune microenvironment by activating the PAR2/IL-6/JAK1/STAT3 axis through MBD3 degradation, leading to PD-L1 upregulation, which may help develop new therapeutic strategies targeting PD-L1 to improve the efficacy of SBRT in HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18